Carol Lisa Rosenberg, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tamoxifen | 6 | 2011 | 981 | 0.590 |
Why?
|
| Loss of Heterozygosity | 3 | 2008 | 684 | 0.470 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2011 | 1524 | 0.450 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2011 | 106 | 0.440 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2008 | 50 | 0.320 |
Why?
|
| Receptors, Progesterone | 2 | 2011 | 1098 | 0.310 |
Why?
|
| Allelic Imbalance | 2 | 2005 | 77 | 0.270 |
Why?
|
| Breast Neoplasms | 9 | 2011 | 20824 | 0.270 |
Why?
|
| Receptors, Estrogen | 3 | 2011 | 2190 | 0.260 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 1097 | 0.220 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2008 | 1100 | 0.220 |
Why?
|
| Receptor, erbB-2 | 2 | 2011 | 2417 | 0.180 |
Why?
|
| BRCA1 Protein | 1 | 2005 | 1149 | 0.170 |
Why?
|
| Germ-Line Mutation | 1 | 2005 | 1788 | 0.150 |
Why?
|
| Citalopram | 2 | 2010 | 403 | 0.140 |
Why?
|
| Mammaplasty | 1 | 2005 | 1204 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5172 | 0.130 |
Why?
|
| Breast | 1 | 2002 | 1970 | 0.110 |
Why?
|
| Carcinoma, Lobular | 2 | 2008 | 484 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2011 | 9240 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2011 | 128 | 0.100 |
Why?
|
| Epithelium | 2 | 2005 | 1679 | 0.080 |
Why?
|
| Breast Neoplasms, Male | 1 | 2011 | 210 | 0.080 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2010 | 503 | 0.070 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2011 | 948 | 0.060 |
Why?
|
| Mastectomy | 1 | 2011 | 1793 | 0.050 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 4328 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2011 | 11031 | 0.050 |
Why?
|
| Age Factors | 2 | 2009 | 18373 | 0.050 |
Why?
|
| Chromosomes | 1 | 2002 | 596 | 0.040 |
Why?
|
| Heterozygote | 1 | 2005 | 2804 | 0.040 |
Why?
|
| Denmark | 2 | 2011 | 738 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2011 | 9849 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2010 | 3444 | 0.040 |
Why?
|
| Middle Aged | 8 | 2011 | 213390 | 0.030 |
Why?
|
| Logistic Models | 2 | 2011 | 13409 | 0.030 |
Why?
|
| Reference Values | 1 | 2002 | 4982 | 0.030 |
Why?
|
| Female | 9 | 2011 | 380193 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 4740 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2009 | 12721 | 0.020 |
Why?
|
| Adult | 7 | 2011 | 214052 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2002 | 3476 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2010 | 61 | 0.020 |
Why?
|
| Humans | 10 | 2011 | 744366 | 0.020 |
Why?
|
| Aged | 6 | 2011 | 163288 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 29060 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 57776 | 0.020 |
Why?
|
| Genotype | 2 | 2011 | 12952 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 1254 | 0.020 |
Why?
|
| Survival Rate | 2 | 2011 | 12788 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 2879 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 3587 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3616 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2011 | 21748 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 3799 | 0.010 |
Why?
|
| Medication Adherence | 1 | 2011 | 2063 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8642 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 6489 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 8091 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2011 | 63107 | 0.010 |
Why?
|
| Depression | 1 | 2010 | 7759 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 23336 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 56429 | 0.000 |
Why?
|
| Risk Factors | 1 | 2010 | 72296 | 0.000 |
Why?
|
| Male | 1 | 2011 | 350115 | 0.000 |
Why?
|